News The curious case of Mylotarg: Pfizer's leukaemia drug set to... Mylotarg backed by advisers after withdrawal in 2010.
News Seattle Genetics leukaemia trial on hold after 4 deaths FDA concerned over potential liver toxicity.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
